JP2017516462A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516462A5
JP2017516462A5 JP2016559329A JP2016559329A JP2017516462A5 JP 2017516462 A5 JP2017516462 A5 JP 2017516462A5 JP 2016559329 A JP2016559329 A JP 2016559329A JP 2016559329 A JP2016559329 A JP 2016559329A JP 2017516462 A5 JP2017516462 A5 JP 2017516462A5
Authority
JP
Japan
Prior art keywords
item
composition
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516462A (ja
JP6836400B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023161 external-priority patent/WO2015149016A2/en
Publication of JP2017516462A publication Critical patent/JP2017516462A/ja
Publication of JP2017516462A5 publication Critical patent/JP2017516462A5/ja
Application granted granted Critical
Publication of JP6836400B2 publication Critical patent/JP6836400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559329A 2014-03-28 2015-03-27 乳がんおよび卵巣がんワクチン Active JP6836400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972176P 2014-03-28 2014-03-28
US61/972,176 2014-03-28
PCT/US2015/023161 WO2015149016A2 (en) 2014-03-28 2015-03-27 Breast and ovarian cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019177337A Division JP2020015755A (ja) 2014-03-28 2019-09-27 乳がんおよび卵巣がんワクチン

Publications (3)

Publication Number Publication Date
JP2017516462A JP2017516462A (ja) 2017-06-22
JP2017516462A5 true JP2017516462A5 (enExample) 2018-06-07
JP6836400B2 JP6836400B2 (ja) 2021-03-03

Family

ID=54196576

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016559329A Active JP6836400B2 (ja) 2014-03-28 2015-03-27 乳がんおよび卵巣がんワクチン
JP2019177337A Withdrawn JP2020015755A (ja) 2014-03-28 2019-09-27 乳がんおよび卵巣がんワクチン
JP2021165941A Active JP7301408B2 (ja) 2014-03-28 2021-10-08 乳がんおよび卵巣がんワクチン
JP2023097667A Active JP7659333B2 (ja) 2014-03-28 2023-06-14 乳がんおよび卵巣がんワクチン
JP2025046658A Active JP7808377B2 (ja) 2014-03-28 2025-03-21 乳がんおよび卵巣がんワクチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019177337A Withdrawn JP2020015755A (ja) 2014-03-28 2019-09-27 乳がんおよび卵巣がんワクチン
JP2021165941A Active JP7301408B2 (ja) 2014-03-28 2021-10-08 乳がんおよび卵巣がんワクチン
JP2023097667A Active JP7659333B2 (ja) 2014-03-28 2023-06-14 乳がんおよび卵巣がんワクチン
JP2025046658A Active JP7808377B2 (ja) 2014-03-28 2025-03-21 乳がんおよび卵巣がんワクチン

Country Status (7)

Country Link
US (4) US10293035B2 (enExample)
EP (1) EP3122375B1 (enExample)
JP (5) JP6836400B2 (enExample)
CN (3) CN113403338B (enExample)
DK (1) DK3122375T3 (enExample)
ES (1) ES2868305T3 (enExample)
WO (1) WO2015149016A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10293035B2 (en) 2014-03-28 2019-05-21 University Of Washington Through Its Center For Commercialization Breast and ovarian cancer vaccines
KR20240038139A (ko) * 2017-12-13 2024-03-22 이노비오 파마수티컬즈, 인크. 서바이빈을 표적으로 하는 암 백신 및 이의 용도
CN109298171B (zh) * 2018-11-15 2022-06-28 武汉中生毓晋生物医药有限责任公司 醛化红细胞中内毒素的去除方法与应用
CN113851187B (zh) * 2021-09-15 2025-05-06 南方科技大学 一种糖肽表位预测方法、存储介质及终端设备
WO2023235771A2 (en) * 2022-05-31 2023-12-07 The University Of Chicago Chemical screen of modulators for vaccine adjuvants

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
EP0651656A1 (en) 1992-07-08 1995-05-10 Schering Corporation Use of gm-csf as a vaccine adjuvant
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6372490B1 (en) * 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein
DE10031122A1 (de) * 1999-06-30 2001-03-22 Max Delbrueck Centrum Mittel zur Diagnose und Therapie maligner Erkrankungen
CA2378097A1 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
WO2001008636A2 (en) * 1999-08-03 2001-02-08 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
DK1276896T3 (da) 2000-04-28 2010-10-18 Mannkind Corp Epitop-synkronisering i antigen-præsenterende celler
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
AU2002950188A0 (en) 2002-07-12 2002-09-12 The University Of Adelaide Altered insulin-like growth factor binding proteins
US7632920B2 (en) * 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
WO2005058967A2 (en) * 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
SI1642905T1 (sl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop
WO2007143023A1 (en) * 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
WO2008008311A1 (en) * 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
JP2010511382A (ja) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
US20090162383A1 (en) 2006-12-26 2009-06-25 Padlan Eduardo A Method for designing vaccines against constantly mutating pathogens
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 cd3―입실론 결합 도메인
CA2694011C (en) 2007-07-19 2016-01-12 Health Research, Inc. Survivin peptides as cancer vaccines
KR101291394B1 (ko) 2007-07-27 2013-08-07 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
WO2009059011A2 (en) 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Hla-dr binding peptides and their uses
EP2270144B8 (en) * 2008-03-31 2017-08-30 tella Inc. Partial peptide of survivin presented on mhc class ii molecule and use thereof
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US8435749B2 (en) 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
US8666674B2 (en) 2009-07-28 2014-03-04 Promising Future, Llc Pairing processes for preparing reactive cytotoxic T cells
EP2519542B1 (en) 2009-12-28 2018-10-10 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
WO2012054589A2 (en) * 2010-10-22 2012-04-26 T2 Biosystems, Inc. Conduit-containing devices and methods for analyte processing and detection
SG192759A1 (en) 2011-02-15 2013-09-30 Immune Design Corp Methods for enhancing immunogen specific immune responses by vectored vaccines
CN103582815A (zh) * 2011-02-24 2014-02-12 佛米利昂公司 用于卵巢癌的生物标志物组、诊断方法和测试试剂盒
US9932386B2 (en) * 2011-04-20 2018-04-03 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
US20170266269A1 (en) 2014-03-28 2017-09-21 University Of Washington Through Its Center For Commercialization Methods of identifying antigens for vaccines
US10293035B2 (en) 2014-03-28 2019-05-21 University Of Washington Through Its Center For Commercialization Breast and ovarian cancer vaccines

Similar Documents

Publication Publication Date Title
US11471527B2 (en) Virus-like particles including HBs-L antigen protein for causing immune response against HBV
JP2017516462A5 (enExample)
JP7248325B2 (ja) 腫瘍および/または癌の処置のための医薬のための単離された組換え体腫瘍溶解性ワクシニアウイルス、医薬組成物、およびそれらの使用
JP2017522312A5 (enExample)
JP2013526837A5 (enExample)
JP2016156828A5 (enExample)
EP3898998A1 (en) Modified orthopoxvirus vectors
JP2016128513A5 (enExample)
KR20180119659A (ko) 항종양 면역을 유도하기 위한 종양 관련 항원의 다중 에피토프를 발현하는 바이러스 벡터
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
JP2019507582A5 (enExample)
JP2018505893A5 (enExample)
US20240344082A1 (en) Viral constructs for use in enhancing t-cell priming during vaccination
JP2017522326A5 (enExample)
JP2015506179A5 (enExample)
CN109200270B (zh) 一种能提高多肽疫苗对hpv感染肿瘤治疗效果的联合用药物及其应用
CN110564767A (zh) 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法
KR102729109B1 (ko) 암을 치료하기 위한 다가 pd-l1 결합 화합물
JP2018528960A5 (enExample)
CN117003856A (zh) 一种靶向乙肝表面抗原的t细胞受体工程化t细胞
CN101096680A (zh) 一种dna疫苗真核表达载体及其在制备基因疫苗中的应用
Sun et al. Recombinant oncolytic vaccinia viruses expressing human β-defensin 2 enhance anti-tumor immunity
KR102135334B1 (ko) 결핵 다가 항원을 발현하는 재조합 아데노 바이러스 및 이를 포함하는 결핵 예방용 조성물
Kawakita et al. ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4+ and CD8+ T-cell responses and neutralizing antibody induction
JP6975716B2 (ja) 樹状細胞標的化ペプチド、当該ペプチドを利用したペプチド融合体、及び当該ペプチド融合体を利用したワクチン